Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A. Younes A, et al. Among authors: ratanatharathorn v. Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20. Lancet Oncol. 2016. PMID: 27451390 Free PMC article. Clinical Trial.
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
Varterasian M, Janakiraman N, Karanes C, Abella E, Uberti J, Dragovic J, Raman SB, al-Katib A, Du W, Silver SM, Adams PT, Sensenbrenner L, Ratanatharathorn V. Varterasian M, et al. Among authors: ratanatharathorn v. Am J Clin Oncol. 1997 Oct;20(5):462-6. doi: 10.1097/00000421-199710000-00005. Am J Clin Oncol. 1997. PMID: 9345328 Clinical Trial.
Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review.
Ayash LJ, Clarke M, Silver SM, Braun T, Uberti J, Ratanatharathorn V, Reynolds C, Ferrara J, Broun ER, Adams PT. Ayash LJ, et al. Among authors: ratanatharathorn v. Bone Marrow Transplant. 2001 May;27(9):939-47. doi: 10.1038/sj.bmt.1703008. Bone Marrow Transplant. 2001. PMID: 11436104 Review.
Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A. Dawson LA, et al. Among authors: ratanatharathorn v. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):208-18. doi: 10.1016/j.ijrobp.2003.07.004. Int J Radiat Oncol Biol Phys. 2004. PMID: 15093918 Clinical Trial.
CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L, Abidi MH, Pray C, Tomaszewski EN, Steele PA, Schalk DL, Yano H, Mitchell A, Dufresne M, Uberti JP, Ratanatharathorn V. Lum LG, et al. Among authors: ratanatharathorn v. Biol Blood Marrow Transplant. 2013 Jun;19(6):925-33. doi: 10.1016/j.bbmt.2013.03.010. Epub 2013 Mar 22. Biol Blood Marrow Transplant. 2013. PMID: 23529012 Free PMC article. Clinical Trial.
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE. Freytes CO, et al. Among authors: ratanatharathorn v. Biol Blood Marrow Transplant. 2014 Dec;20(12):1949-57. doi: 10.1016/j.bbmt.2014.08.007. Epub 2014 Aug 16. Biol Blood Marrow Transplant. 2014. PMID: 25139216 Free article. Clinical Trial.
195 results